CHINARES PHARMA subsidiary TASLY earned 1.105 billion RMB for the year, an increase of 15.6%

China Resources Pharmaceutical (03320.HK) announced that its subsidiary TASLY (600535.SH) achieved an operating revenue of 8.236 billion (RMB) for the fiscal year 2025, a year-on-year decrease of 3.1%. The net profit attributable to shareholders was 1.105 billion, an increase of 15.6%, with earnings per share of 0.74